The company also announced a major portfolio shift, planning to divest its Immunodiagnostics business in China, a unit that generated approximately 6% of its fiscal 2025 revenue
The company’s Growth Portfolio delivered $6.2 billion in revenue
Growth was supported by stronger COVID vaccine sales and expanded government supply agreements in international markets
Lifts full-year outlook as obesity drug boom accelerates
The renewal covers two versions of the IQOS device and three HEETS tobacco variants
Under the terms, Arcellx shareholders received $115 per share in cash plus a non-transferable contingent value right
But acquisition charges drag earnings into loss
The medtech firm strengthens its full-stack remote cardiac monitoring platform, achieves 11x revenue growth, and advances its global expansion plans
With big pharma leaning on external pipelines, the company sees opportunity in de-risked, high-impact assets with clear clinical endpoints
India leads the shift as wellness tourism integrates healthcare, hospitality, and lifestyle
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
